Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for FB102 in Celiac Disease. The expected timing is based on the latest available company guidance and may change.
6/23/25- Announced Ph1b study. Ph2 trial initiating, Topline data in 2026. 9/15/25- Presented additional data at Tampere Celiac Disease Symposium. 11/14/25:- US IND open; Ph2 CeD trial enrolling US sites; topline data still expected in 2026. 03/31/26:- Phase 2 celiac study topline results still expected in 2026; key efficacy data readout pending. 05/11/26:- Received FDA Fast Track in celiac disease; Ph2 topline results still expected in 2026.
Verification
Confirm timing and program details against the company announcement or filing.